Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance at beginning of period (in shares) at Dec. 31, 2020	15,079,329
Balance at beginning of period at Dec. 31, 2020	$ 38,914
Balance at end of period (in shares) at Mar. 31, 2021	15,079,329
Balance at end of period at Mar. 31, 2021	$ 38,914
Balance at beginning of period (in shares) at Dec. 31, 2020		5,023,957
Balance at beginning of period at Dec. 31, 2020	(25,459)	$ 2	$ 851	$ (26,312)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		223,216
Issuance of Common Stock upon exercise of stock options	133		133
Stock-based compensation expense	67		67
Net loss	(7,442)			(7,442)
Balance at end of period (in shares) at Mar. 31, 2021		5,247,173
Balance at end of period at Mar. 31, 2021	$ (32,701)	$ 2	1,051	(33,754)
Balance at beginning of period (in shares) at Dec. 31, 2020	15,079,329
Balance at beginning of period at Dec. 31, 2020	$ 38,914
Balance at beginning of period (in shares) at Dec. 31, 2020		5,023,957
Balance at beginning of period at Dec. 31, 2020	(25,459)	$ 2	851	(26,312)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(16,643)
Balance at end of period (in shares) at Jun. 30, 2021		29,291,563
Balance at end of period at Jun. 30, 2021	$ 112,437	$ 5	155,387	(42,955)
Balance at beginning of period (in shares) at Mar. 31, 2021	15,079,329
Balance at beginning of period at Mar. 31, 2021	$ 38,914
Balance at beginning of period (in shares) at Mar. 31, 2021		5,247,173
Balance at beginning of period at Mar. 31, 2021	(32,701)	$ 2	1,051	(33,754)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		45,929
Issuance of Common Stock upon exercise of stock options	25		25
Stock-based compensation expense	146		146
Net loss	(9,201)			(9,201)
Issuance of common shares upon initial public offering, net of issuance costs (in shares)		7,666,664
Issuance of common shares upon initial public offering, net of issuance costs of $8,587	$ 112,484	$ 1	112,483
Conversion of convertible preferred shares into an equivalent number of common shares (in shares)	(15,079,329)
Conversion of shares of convertible preferred stock into an equivalent number of shares of common stock	$ (38,914)
Conversion of convertible preferred shares into an equivalents number of common shares (in shares)		15,079,329
Conversion of shares of convertible preferred stock into an equivalent number of shares of common stock	38,914	$ 2	38,912
Issuance of Common Stock upon exercise of stock options (in shares)		1,252,468
Issuance of warrant and conversion into shares of common stock	2,770		2,770
Balance at end of period (in shares) at Jun. 30, 2021		29,291,563
Balance at end of period at Jun. 30, 2021	$ 112,437	$ 5	155,387	(42,955)
Balance at beginning of period (in shares) at Dec. 31, 2021	29,318,578	29,318,578
Balance at beginning of period at Dec. 31, 2021	$ 90,784	$ 5	156,049	(65,270)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		70,534
Issuance of Common Stock upon exercise of stock options	78		78
Stock-based compensation expense	448		448
Unrealized loss on available- for-sale short-term investments	(16)				$ (16)
Net loss	(13,194)			(13,194)
Balance at end of period (in shares) at Mar. 31, 2022		29,389,112
Balance at end of period at Mar. 31, 2022	$ 78,100	$ 5	156,575	(78,464)	(16)
Balance at beginning of period (in shares) at Dec. 31, 2021	29,318,578	29,318,578
Balance at beginning of period at Dec. 31, 2021	$ 90,784	$ 5	156,049	(65,270)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	82,286
Unrealized loss on available- for-sale short-term investments	$ (34)
Net loss	$ (28,025)
Balance at end of period (in shares) at Jun. 30, 2022	29,514,071	29,514,071
Balance at end of period at Jun. 30, 2022	$ 64,720	$ 5	158,044	(93,295)	(34)
Balance at beginning of period (in shares) at Mar. 31, 2022		29,389,112
Balance at beginning of period at Mar. 31, 2022	78,100	$ 5	156,575	(78,464)	(16)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		11,752
Issuance of Common Stock upon exercise of stock options	12		12
Issuance of Common Stock related to ESPP (in shares)		113,207
Issuance of Common Stock related to ESPP	339		339
Stock-based compensation expense	1,118		1,118
Unrealized loss on available- for-sale short-term investments	(18)				(18)
Net loss	$ (14,831)			(14,831)
Balance at end of period (in shares) at Jun. 30, 2022	29,514,071	29,514,071
Balance at end of period at Jun. 30, 2022	$ 64,720	$ 5	$ 158,044	$ (93,295)	$ (34)